Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human lactoferrin
- Development stage
- Unknown
- Lead developer
- Ventria Bioscience
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral, Intraperitoneal
01
Overview
Recombinant human lactoferrin (rhLF) is a multifunctional protein produced through recombinant technology, often in hosts like rice, yeast (*Komagataella phaffii*), or fungi (*Trichoderma reesei*). It is being developed for various therapeutic applications, including the treatment of advanced renal cell carcinoma, prevention of antibiotic-associated diarrhea, and severe sepsis. Additionally, it is investigated for its effects on chronic inflammation and cognitive deterioration in the elderly, and for managing *Clostridium difficile* infection. rhLF also shows promise as a food ingredient for immune support in healthy adults, exhibiting anti-inflammatory, antibacterial, and antitumor properties. Its mechanism involves modulating immune responses, such as inhibiting the Toll-like receptor 4-nuclear factor-kappa B pathway, upregulating ERK 1 and 2 phosphorylation, and attenuating microglial activation.
- Brand names
- Effera
- Other names
- talactoferrinrecombinant human lactoferrin
02
Targets
IL-6 (Interleukin 6)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on recombinant human lactoferrin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human lactoferrin.